North American Vaccine Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : North American Vaccine

NVX 0.985

-5.3%

Jan 30 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: David Bogdanoff who wrote (185)	12/26/1997 8:13:00 AM
From: Don W Stone	Read Replies (1) of 507

David: Are you trying to appeal to fear, generate emotions? Have you read the 10Q on either of these companies? Are you fasbricating this stuff? How do you support your ideas? Starting with VIVUS: 1. Approval came last january ( not recently as you elude to.) 2. The product did't perform to expectations i.e. 40% effective at best when 60% or better was expected. 3. They had manufacturing problems so they said. 4. Sales went to hell. 5. Pfizer has a far better product coming out in mid '98. 6. Five of 7 analyst downgraded the stock. and7. They got bombed bigtime by a recent Barrons article. The stock has been in a steady decline for at least 4 months. Now that doesn't seem to resemble anything that you surmised from the company and it can hardly give one any insite about how NVX mite behave in the near future. Now Ligent: Apparently this is a hot little well followed company. I can't find any information about receiving any FDA approval ever and i doubt they have even applied. This company is in the early stages of product development. Has alliances with everyone. Their revenue comes solely from those alliances. Apparently some think it could prove to be a big winner some day. Possible, but that time is still a few years out and then some. Just mite prove to be an excellent long term investment and one to accumulate on weakness. The stock isn't "unknown". They are projected to loose $1.35 in'97 and .87 in'98. It has been in a steady decline since the first week in Oct giving up about 30% from its high. Hard to account for exactly why. Developement stage companies tend to move on milestone achievements, alliance announcements, and analyst recommendations. My guess is it has been quiet for a while. ONce again I can't relate this company at all to the stage at which NVX is at in its development. Neither of these companies or there situations provide any insite into how NVX mite react upon FDA approval. I would like to think your intention was to contribute insite rather than influence but I think the latter to be more likely. Go back and read up on both companies and than reread and reread and reread. Next go study everything that is a part of NVX's homepage. :-}, :-}.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next